Niclosamide (NA) overcomes cisplatin resistance in human ovarian cancer

被引：7
|
作者：
Huang, Linjuan [1 ,2 ,3 ,4 ]
Zhang, Jing [1 ,2 ,3 ,4 ]
Deng, Youling [1 ,2 ,3 ,4 ]
Wang, Hao [4 ,5 ,6 ]
Zhao, Piao [1 ,2 ,3 ,4 ]
Zhao, Guozhi [1 ,2 ,3 ,4 ]
Zeng, Wei [4 ,7 ]
Wang, Yonghui [4 ,8 ]
Chen, Connie [4 ]
Wagstaff, William [4 ]
Haydon, Rex C. [4 ]
Reid, Russell R. [4 ,9 ]
He, Tong-Chuan [4 ,10 ]
Shen, Le [4 ,10 ]
Luu, Hue H. [4 ]
Zhao, Ling [1 ,2 ,3 ,4 ]
机构：
[1] Chongqing Med Univ, Affiliated Hosp 1, Dept Obstet & Gynecol, Chongqing 400046, Peoples R China
[2] Chongqing Med Univ, Affiliated Hosp 1, Dept Orthopaed Surg, Chongqing 400046, Peoples R China
[3] Chongqing Med Univ, Affiliated Hosp 1, Dept Urol, Chongqing 400046, Peoples R China
[4] Univ Chicago, Med Ctr, Dept Orthopaed Surg & Rehabil Med, Mol Oncol Lab, Chicago, IL 60637 USA
[5] Chongqing Med Univ, Minist Educ, Sch Lab Med, Key Lab Diagnost Med, Chongqing 400016, Peoples R China
[6] Chongqing Med Univ, Sch Lab Med, Chongqing 400016, Peoples R China
[7] Jianghan Univ, Affiliated Hosp 2, Dept Neurol, Wuhan 430050, Hubei, Peoples R China
[8] Shanghai Jiao Tong Univ, Sch Med, Dept Clin Lab Med, Shanghai 200000, Peoples R China
[9] Univ Chicago, Med Ctr, Dept Surg Sect Plast Surg, Lab Craniofacial Suture Biol & Dev, Chicago, IL 60637 USA
[10] Univ Chicago, Med Ctr, Dept Surg, Chicago, IL 60637 USA
来源：
GENES & DISEASES | 2023年 / 10卷 / 04期
基金：
美国国家卫生研究院;
关键词：
Chemotherapy resistance; Cisplatin; Drug repurposing; Niclosamide; Ovarian cancer; MESENCHYMAL STEM-CELLS; BMP9-INDUCED OSTEOGENIC DIFFERENTIATION; SUPPRESSES TUMOR-GROWTH; WNT/BETA-CATENIN; ANTIHELMINTHIC NICLOSAMIDE; OSTEOBLAST DIFFERENTIATION; GENE-EXPRESSION; INHIBITION; PATHWAY; PROLIFERATION;
D O I：
10.1016/j.gendis.2022.12.005
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Ovarian cancer (OC) is one of the most lethal malignancies of the female reproduc-tive system. OC patients are usually diagnosed at advanced stages due to the lack of early diag-nosis. The standard treatment for OC includes a combination of debulking surgery and platinum-taxane chemotherapy, while several targeted therapies have recently been approved for maintenance treatment. The vast majority of OC patients relapse with chemoresistant tu-mors after an initial response. Thus, there is an unmet clinical need to develop new therapeu-tic agents to overcome the chemoresistance of OC. The anti-parasite agent niclosamide (NA) has been repurposed as an anti-cancer agent and exerts potent anti-cancer activities in human cancers including OC. Here, we investigated whether NA could be repurposed as a therapeutic
引用
收藏
页码：1687 / 1701
页数：15
相关论文
共 50 条
  • [31] Expression of human dCTP pyrophosphatase 1 (DCTPP1) and its association with cisplatin resistance characteristics in ovarian cancer
    Wang, Yu
    Chen, Xiangyun
    Chen, Qiduan
    Liu, Tiancai
    Wu, Yingsong
    Huang, Liping
    Chen, Yao
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2024, 28 (09)
  • [32] Combinations of Resveratrol, Cisplatin and Oxaliplatin Applied to Human Ovarian Cancer Cells
    Nessa, Meher U.
    Beale, Philip
    Chan, Charles
    Yu, Jun Q.
    Huq, Fazlul
    ANTICANCER RESEARCH, 2012, 32 (01) : 53 - 59
  • [33] The synergistic mechanisms of propofol with cisplatin or doxorubicin in human ovarian cancer cells
    Sue, Sung-How
    Tseng, Wei-Cheng
    Wu, Zih-Syuan
    Huang, Shih-Ming
    Chen, Jia-Lin
    Wu, Zhi-Fu
    Lai, Hou-Chuan
    JOURNAL OF OVARIAN RESEARCH, 2024, 17 (01)
  • [34] Reversing drug resistance of cisplatin by hsp90 inhibitors in human ovarian cancer cells
    Zhang, Zhengmao
    Xie, Zhen
    Sun, Guangyu
    Yang, Pingfang
    Li, Jia
    Yang, Hongfang
    Xiao, Shuang
    Liu, Yang
    Qiu, Hongbing
    Qin, Lijun
    Zhang, Chao
    Zhang, Fenghua
    Shan, Baoen
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 8 (05): : 6687 - 6701
  • [35] Choline kinase alpha impairment overcomes TRAIL resistance in ovarian cancer cells
    Rizzo, Andrea
    Satta, Alessandro
    Garrone, Giulia
    Cavalleri, Adalberto
    Napoli, Alessandra
    Raspagliesi, Francesco
    Figini, Mariangela
    De Cecco, Loris
    Iorio, Egidio
    Tomassetti, Antonella
    Mezzanzanica, Delia
    Bagnoli, Marina
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2021, 40 (01)
  • [36] The Impact of Integrin-Mediated Matrix Adhesion on Cisplatin Resistance of W1 Ovarian Cancer Cells
    von Rekowski, Kathleen Wantoch
    Koenig, Philipp
    Henze, Svenja
    Schlesinger, Martin
    Zawierucha, Piotr
    Januchowski, Radoslaw
    Bendas, Gerd
    BIOMOLECULES, 2019, 9 (12)
  • [37] FOXO3a Reverses the Cisplatin Resistance in Ovarian Cancer
    Lu, Mudan
    Chen, Xuan
    Xiao, Jianping
    Xiang, Jingying
    Yang, Lan
    Chen, Daozhen
    ARCHIVES OF MEDICAL RESEARCH, 2018, 49 (02) : 84 - 88
  • [38] MicroRNAs as the critical regulators of Cisplatin resistance in ovarian cancer cells
    Meysam Moghbeli
    Journal of Ovarian Research, 14
  • [39] MicroRNAs as the critical regulators of Cisplatin resistance in ovarian cancer cells
    Moghbeli, Meysam
    JOURNAL OF OVARIAN RESEARCH, 2021, 14 (01)
  • [40] Purvalanol A induces apoptosis and reverses cisplatin resistance in ovarian cancer
    Zhang, Xiaoyi
    Hong, Shasha
    Yang, Jiang
    Liu, Jingchun
    Wang, Ying
    Peng, Jiaxin
    Wang, Haoyu
    Hong, Li
    ANTI-CANCER DRUGS, 2023, 34 (01) : 29 - 43
12345